TY - JOUR T1 - Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications JF - Evidence Based Medicine JO - Evid Based Med SP - 7 LP - 7 DO - 10.1136/ebmed-2014-110046 VL - 20 IS - 1 AU - Barbara Michiels Y1 - 2015/02/01 UR - http://ebm.bmj.com/content/20/1/7.abstract N2 - Commentary on: Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2547.OpenUrlAbstract/FREE Full TextThe neuraminidase inhibitor zanamivir, administered as an inhaled powder, is approved for the prevention and treatment of influenza in adults and children older than 7 years. Previous systematic reviews (SRs) of zanamivir may have been affected by publication bias and missing data, and clinical recommendations based on such studies should be considered inadequate.1 ,2 To deal with these shortcomings, this SR and meta-analysis (an update of a Cochrane Review)3 reanalysed the prophylactic and treatment effects of zanamivir on those suffering from influenza, based on the full clinical study reports of all relevant trials provided by the manufacturer and on regulatory comments.This review included randomised controlled trials (RCTs) testing zanamivir compared with placebo for … ER -